ADVANCED MEDICAL SOLUTIONS GROUP PLC — Earnings Release 2018

Dec 18, 2018

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 7430K

Advanced Medical Solutions Grp PLC

18 December 2018

	18 December 2018

Advanced Medical Solutions Group plc

("AMS" or the "Group")

Trading Update

Winsford, UK, 18 December 2018: Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced woundcare specialist company, today announces an update on trading for the year ending 31 December 2018.

The Group continues to make good progress and the Board expects results to be in line with current market expectations.

Chris Meredith, Chief Executive Officer of AMS, said: "The Group continues to deliver good growth supported by innovative product development and is well positioned for the future."

The Group expects to publish its Preliminary Results for the year to 31 December 2018 in March 2019.

- End -

For further information, please contact:

Advanced Medical Solutions Group plc	#### Tel: +44 (0) 1606 545508
Chris Meredith, Chief Executive Officer Mary Tavener, Chief Financial Officer
Consilium Strategic Communications	Tel: +44 (0) 20 3709 5700
Mary-Jane Elliott / Matthew Neal / Nicholas Brown / Olivia Manser
Investec Bank plc (NOMAD) & Broker	Tel: +44 (0) 20 7597 5970
Daniel Adams / Gary Clarence / Patrick Robb

About Advanced Medical Solutions Group plc

AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical and wound care markets, focused on quality outcomes for patients and value for payers. AMS has a wide range of products that include tissue adhesives, sutures, haemostats, internal fixation devices, silver alginates, alginates and foams, which it markets under its brands LiquiBand®, RESORBA®, LiquiBand® Fix8™ and ActivHeal® as well as supplying under white label.

AMS's products, manufactured out of two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic, are sold in 77 countries via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, the Czech Republic and Russia. Established in 1991, the Group has approximately 650 employees. For more information please see www.admedsol.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

TSTLLFIDFSLDLIT